Antibody-Based Therapies Effective At Controlling Malaria

Main Category: Tropical Diseases
Also Included In: Immune System / Vaccines
Article Date: 18 May 2007 - 12:00 PDT

email to a friend   printer friendly   opinions  

Passive immunization through the development of fully human antibodies specific to Plasmodium falciparum may be effective at controlling the disease, report researchers led by Dr. Richard S. McIntosh from the University of Nottingham in a paper published this week in the open-access journal PLoS Pathogens. The researchers developed these novel reagents by antibody repertoire cloning generated from immune Gambian adults.

While it remains unclear if in vitro assays are predictive of functional immunity in humans, due to the lack of suitable animal models, according to this study antimalarial efficacy of human antibodies can be determined using rodent malaria parasites transgenic for P. falciparum antigens in mice and humans. An in vivo mouse model has significant advantage over the use of new world primates, the only other model for human malaria, which are labor-intensive and difficult to reproduce.

These novel human reagents cured mice of an otherwise lethal malaria infection, and protection was crucially dependent on human antibody receptors.

Malaria currently rivals HIV and tuberculosis as the world's most deadly infection, killing two to three million people a year or roughly one person every 30 seconds. The model described in this study provides both a test for therapeutic antibody efficacy prior to clinical trials in humans and an important tool in malaria vaccine development.

This study was supported by a Medical Research Council Career Establishment Award, a European Union Marie Curie Excellence Grant, Antibody Immunotherapy for Malaria, and a ROPA (Realizing Our Potential Award).

Open-access journal PLoS Pathogens - www.plospathogens.org

McIntosh RS, Shi J, Jennings RM, Chappel JC, de Koning-Ward TF, et al. (2007)
The importance of human FcγRI in mediating protection to malaria
PLoS Pathog 3(5):
e72. doi:10.1371/journal.ppat.0030072
www.dx.doi.org/10.1371/journal.ppat.0030072

Disclaimer

This press release refers to an upcoming article in PLoS Pathogens. The release is provided by journal staff. Any opinions expressed in these releases or articles are the personal views of the journal staff and do not necessarily represent the views or policies of PLoS. PLoS expressly disclaims any and all warranties and liability in connection with the information found in the releases and articles and your use of such information.

About PLoS Pathogens

All works published in PLoS Pathogens are open access. Everything is immediately available without cost to anyone, anywhere-to read, download, redistribute, include in databases, and otherwise use-subject to the condition that the original authorship is properly attributed. Copyright is retained by the authors. The Public Library of Science uses the Creative Commons Attribution License.

About the Public Library of Science

The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit www.plos.org

• Additional
• References
• Citations